Xarelto (rivaroxaban) is a new generation blood thinner which was approved by the FDA on July 1, 2011. Xarelto has been approved to prevent deep vein thrombosis after knee replacement surgery and hip replacement surgery and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The most dangerous side effect for people taking Xarelto is uncontrollable bleeding. The manufacturers of Xarelto claim that blood tests are not needed for patients taking this drug. Because Xarelto’s ability to thin blood varies widely between patients, the lack of a simple blood-test prevents patients and physicians from knowing whether Xarelto causes a patient’s blood to become too thin leading to uncontrolled bleeding events.
Hare Wynn is currently investigating the following injuries related to the use of Xarelto:
- Irreversible bleeding
- Gastrointestinal bleeding
- Intracranial bleeding
If you or a loved one has taken Xarelto and have developed any of these injuries, please contact us. We are currently evaluating claims.